🇺🇸 US

CYTK revenue, net income and debt history (Cytokinetics, Incorporated)

Quick answer

Cytokinetics, Incorporated (CYTK) reported revenue of $88.0M and net loss of $785.0M for the fiscal year ended 2025-12-31, up 376.6% from $18.5M the year before, per its 10-K filed with the SEC on 2026-02-26. Long-term debt stood at $246.4M.

✓ SEC EDGAR XBRL company facts (10-K/10-Q filings)

Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)

Fiscal yearRevenueNet incomeLong-term debt
2025 (FY ending 2025-12-31)$88.0M-$785.0M$246.4M
2024 (FY ending 2024-12-31)$18.5M-$589.5M$619.5M
2023 (FY ending 2023-12-31)$7.5M-$526.2M$639.3M
2022 (FY ending 2022-12-31)$94.6M-$389.0M$649.6M
2021 (FY ending 2021-12-31)$70.4M-$215.3M$47.4M
2020 (FY ending 2020-12-31)$55.8M-$127.3M$46.2M
2019 (FY ending 2019-12-31)$26.9M-$121.7M$45.1M
2018 (FY ending 2018-12-31)$31.5M-$106.3M$42.4M
2017 (FY ending 2017-12-31)$13.4M-$127.8M$31.8M
2016 (FY ending 2016-12-31)$106.4M$16.5M$29.9M

Related

Last updated 2026-10-16. Data only, not financial or tax advice.